Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy?

被引:107
作者
Aloia, Thomas E.
Lee, Jeffrey E.
Vauthey, Jean-Nicolas
Abdalla, Eddie K.
Wolff, Robert A.
Varadhachary, Gauri R.
Abbruzzese, James L.
Crane, Christopher H.
Evans, Douglas B.
Pisters, Peter W. T.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Oncol, Unit 444, Houston, TX 77230 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77230 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77230 USA
关键词
D O I
10.1016/j.jamcollsurg.2006.12.011
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Delayed recovery after pancreaticoduodenectomy (PD) is believed to preclude adjuvant therapy for approximately 30% of patients who undergo elective PD as initial treatment for pancreatic adenocarcinoma. This study reexamined the frequency of delayed recovery and assessed other factors associated with adjuvant therapy administration after PD at a high-volume center. STUDY DESIGN: Preoperative and perioperative variables were reviewed in a consecutive series of 85 patients with pancreatic adenocarcinoma undergoing PD without preoperative chemotherapy or radiotherapy from 1990 to 2004. RESULTS: Study groups included patients undergoing emergency PD (group 1, n = 13); elective PD with good preoperative Eastern Cooperative Oncology Group (ECOG) performance status (PS) (group 2, ECOG PS: 0 to 1, n = 63); and elective PD with marginal preoperative PS (group 3, ECOG PS: 2 to 3, n = 9). Delayed recovery of PS precluded adjuvant therapy in 23% of patients in group 1, 6% of patients in group 2, and 44% of patients in group 3 (p = 0.0001) CONCLUSIONS: The impact of delayed recovery after PD on the delivery of adjuvant therapy depends on the urgency of surgery and the preoperative PS. For patients with good preoperative PS who undergo elective PD at a high-volume center, it is uncommon for delayed recovery to preclude delivery of adjuvant therapy.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 24 条
  • [1] [Anonymous], 1987, Cancer, V59, P2006
  • [2] ADJUVANT COMBINATION CHEMOTHERAPY (AMF) FOLLOWING RADICAL RESECTION OF CARCINOMA OF THE PANCREAS AND PAPILLA OF VATER - RESULTS OF A CONTROLLED, PROSPECTIVE, RANDOMIZED MULTICENTER STUDY
    BAKKEVOLD, KE
    ARNESJO, B
    DAHL, O
    KAMBESTAD, B
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) : 698 - 703
  • [3] Impact of hospital volume on operative mortality for major cancer surgery
    Begg, CB
    Cramer, LD
    Hoskins, WJ
    Brennan, MF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20): : 1747 - 1751
  • [4] Bottger TC, 1999, HEPATO-GASTROENTEROL, V46, P2589
  • [5] Estimates of cancer incidence and mortality in Europe in 1995
    Bray, F
    Sankila, R
    Ferlay, J
    Parkin, DM
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) : 99 - 166
  • [6] Brennan Murray F, 2004, Surg Oncol Clin N Am, V13, P555
  • [7] Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration
    Breslin, TM
    Hess, KR
    Harbison, DB
    Jean, ME
    Cleary, KR
    Dackiw, AP
    Wolff, RA
    Abbruzzese, JL
    Janjan, NA
    Crane, CIH
    Vauthey, JN
    Lee, JE
    Pisters, PWT
    Evans, DB
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (02) : 123 - 132
  • [8] Dicarlo V, 1998, BRIT J SURG, V85, P607
  • [9] THE EFFECTS OF REGIONALIZATION ON COST AND OUTCOME FOR ONE GENERAL HIGH-RISK SURGICAL-PROCEDURE
    GORDON, TA
    BURLEYSON, GP
    TIELSCH, JM
    CAMERON, JL
    [J]. ANNALS OF SURGERY, 1995, 221 (01) : 43 - 49
  • [10] Cancer statistics, 2005
    Jemal, A
    Murray, T
    Ward, E
    Samuels, A
    Tiwari, RC
    Ghafoor, A
    Feuer, EJ
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) : 10 - 30